

Center Report to the SNMMI Board of Directors June 2019

Therapy Center of Excellence

Center Mission: Therapy CoE is an organizational component within the SNMMI dedicated to all aspects of the development and utilization of Targeted Radioisotope Therapy (TRT) as an alternative to other treatments. Specifically, the center will bring together a centralized group of all constituents within this area creating a multi-disciplinary interest group whereby industry, pharma, physicians, scientists, government and regulatory agencies as well as other stakeholders can convene to share ideas, develop education offerings and advance the utilization of radionuclide therapy.

The Therapy Center of Excellence:

- (a) Provides a forum for members with similar interests
- (b) Provides expertise in TRT
- (c) Fosters research and education in TRT
- (d) Provides outreach to other professionals and organizations
- (e) Nurtures new membership in SNMMI

Center Mission and SNMMI's Strategic Plan: The work of the Therapy Center applies to the following goals and objectives in SNMMI's Strategic Plan:

Goal A: SNMMI members are known for high-quality, value-driven performance and delivery of patient-centered nuclear medicine practice.

Objective 4. Expand continuing education options for practitioners.

Goal B: SNMMI has advanced the development and approval of nuclear medicine and molecular imaging technologies.

Objective 1: Encourage and promote research in the field

Objective 2: Increase the number of initiatives targeting the discovery and validation of diagnostic radiopharmaceuticals, radiotherapeutics and instrumentation.

Goal E: Patients and the medical community recognize the value of nuclear medicine, molecular imaging and radionuclide therapy.

Objective 3. Improve collaboration with other medical societies.

Goal F: SNMMI has the organizational strength and sustainability to lead the field in a dynamic healthcare landscape.

Objective 1: Strengthen membership numbers.

d. Ensure enthusiasm.

iii. Create a sense of community and networking opportunities among our members.

Therapy CoE President: Dan Pryma, MD

SNMMI Board members appointed to Therapy CoE Board: Bennett S. Greenspan, MD, FACNM, FACR; Jon Baldwin, DO; Suzanne Lapi, PhD

Date of Last meeting: January 2019

Date of Next meeting: June 23, 2019

Update on Programs of the Center:

2019 SNMMI Mid-Winter Meeting CE sessions – MWM focused on Therapy:

- Molecular and Genomic Theranostics in Thyroid Cancer: The Evolving Role for Nuclear Medicine-with GCNMC
- Theranostic Agents: What's New and what's on the Horizon-with CTN and PET CoE
- Nuts & Bolts of Using PRRT-with PET CoE and CTN

2019 SNMMI Annual Meeting Categorical Sessions:

 Thyroid Cancer Theranostics - The Evolving Role for Nuclear Medicine in Clinical Genomics Paradigm

2019 SNMMI Annual Meeting CE Session:

- Prostate Cancer Nuts and Bolts: Diagnosis and Therapy
- Differentiated Thyroid Cancer Theranostics Practicum
- Current Uses of MIBG and New Directions
- Saul Hertz Award Symposium: The Atomic Cocktail of Radioiodine Ushers in Precision Oncology
- The Era of PRRT: Personalization, Integration and Future Perspectives

Outreach Meetings:

- Multilateral Conference of Differentiated Thyroid Cancer
- Roundtable discussion on Targeted Radiotherapy with NCI

Action Items in Progress/Pending:

- Launching additional committees of the Center
- Establishing the Therapy Center newsletter
- Follow-up with NCI on the TRT meeting
- ThyCa Initiative: bringing together local nuclear medicine physicians and ThyCa chapter facilitators to coordinate pro bono presentations by nuclear medicine physician in the region of the various ThyCa chapters on radioiodine imaging and therapy. Develop educational modules for these speakers.
- Clarify the SNMMI structure as pertains to companion diagnostics related to therapeutic radiopharmaceuticals and whether they fall under the purview of this Center. To that end, proposal of name change to the SNMMI BoD at the 2019 SNMMI Annual Meeting

Action Items Completed: See programs above

Recommendations/Questions for the Board of Directors: N/A

Other Comments: N/A